
Wuhan Newtop BiotechRetatrutide
Ordered Retatrutide from Wuhan Newtop Biotech? Mail in a sample (US only) and let us test it.
Test my supplyWuhan Newtop Biotech Retatrutide is pulled down by recent purity misses after an earlier clean run. Nov same-batch results were 98.53–99.11% purity, with 10 mg vials as low as 8.12 mg; later lots will show whether the issue persists.
We investigated who actually operates Wuhan Newtop Biotech — corporate records, ownership trails, web infrastructure, and how its lab results break down product by product. Read the full report before you order.
Unlock original COAs
View and download original lab PDFs for Finnrick tests, including Wuhan Newtop Biotech rows.
Cancel anytime
About Wuhan Newtop Biotech test results from Finnrick
Wuhan Newtop Biotech is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 2 peptides and 10 tests, including ratings, observed price signals, recent test dates, and correction history where available.
Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.
The most visible Wuhan Newtop Biotech peptides in this dataset are GHK-Cu (1 test), Retatrutide (9 tests) and NAD+ (0 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.
Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 10 recent tests.
Ordered Retatrutide from Wuhan Newtop Biotech? Mail in a sample (US only) and let us test it.
Test my supply